Barclays initiated coverage of Quest Diagnostics with an Equal Weight rating and $145 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics price target raised to $150 from $145 at Truist
- Quest Diagnostics names Yuri A. Fesko, M.D., as Chief Medical Officer
- Quest Diagnostics management to meet with Truist
- Quest Diagnostics price target raised by $4 at JPMorgan, here’s why
- Quest Diagnostics just upgraded at BofA, here’s why